Was It Worth It? A Mature Reappraisal of Anti-CD20 Maintenance for Follicular Lymphoma During the COVID-19 Pandemic

Background: Anti-CD20 maintenance prolongs progression-free survival (PFS) in follicular lymphoma (FL) but sustains B-cell depletion and blunts vaccine responses. Methods: we conducted a retrospective study comparing two Italian centres that, during the COVID-19 pandemic, adopted opposite policies: Centre A continued maintenance; Centre B discouraged it. Results: Among 62 consecutive patients completing first- or second-line induction in 2019–2022, maintenance was started in 47 (95% and 41% by centre; 92% and 27% among patients aged ≥70 years); patients not receiving it were older (79 vs. 66 years, p < 0.001). After a median follow-up of 70 months, crude 5-year PFS favoured maintenance (59% vs. 27%; hazard ratio [HR] 0.39), but the advantage shrank after adjustment for age (HR 0.72, 95% CI 0.30–1.72) or overlap propensity weighting (HR 0.60, 0.27–1.31); overall survival did not differ. The strong association between more than four cycles and survival (HR 0.22) faded at a 12-month landmark (HR 0.61, 0.19–1.95), consistent with immortal-time bias. All five COVID-19 deaths (10.6%) occurred in maintained patients, 2.0–3.7 months after the last dose and mostly without seroconversion, and none among the older patients without maintenance. Censoring these deaths brought the PFS benefit back within the range of randomised trials (weighted HR 0.41, 0.17–0.96). Conclusions: In this small real-world cohort, COVID-19 mortality appears to have offset much of the expected gain from maintenance during the pandemic.

Authors

Institutions

Publication Details

Journal
Antibodies
Published
2026-11-19
DOI
https://doi.org/10.3390/antib15060110
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Was It Worth It? A Mature Reappraisal of Anti-CD20 Maintenance for Follicular Lymphoma During the COVID-19 Pandemic

Pietro Lauzzana, Elisa Lucchini, Raffaella Pasquale, Francesco F. Zaja et al.
Antibodies
Lymphoma Diagnosis and Treatment
article

Was It Worth It? A Mature Reappraisal of Anti-CD20 Maintenance for Follicular Lymphoma During the COVID-19 Pandemic

Pietro Lauzzana, Elisa Lucchini, Raffaella Pasquale, Francesco F. Zaja, Laura Ballotta, Mario Ballerini, Francesca F. Patriarca, Jacopo Olivieri, Giuseppe Petruzzellis, Renato R. Fanin, Massimo Moratti, Rosa Plos, Valeria Liotta, Matteo Turoldo
article en

Abstract

Background: Anti-CD20 maintenance prolongs progression-free survival (PFS) in follicular lymphoma (FL) but sustains B-cell depletion and blunts vaccine responses. Methods: we conducted a retrospective study comparing two Italian centres that, during the COVID-19 pandemic, adopted opposite policies: Centre A continued maintenance; Centre B discouraged it. Results: Among 62 consecutive patients completing first- or second-line induction in 2019–2022, maintenance was started in 47 (95% and 41% by centre; 92% and 27% among patients aged ≥70 years); patients not receiving it were older (79 vs. 66 years, p < 0.001). After a median follow-up of 70 months, crude 5-year PFS favoured maintenance (59% vs. 27%; hazard ratio [HR] 0.39), but the advantage shrank after adjustment for age (HR 0.72, 95% CI 0.30–1.72) or overlap propensity weighting (HR 0.60, 0.27–1.31); overall survival did not differ. The strong association between more than four cycles and survival (HR 0.22) faded at a 12-month landmark (HR 0.61, 0.19–1.95), consistent with immortal-time bias. All five COVID-19 deaths (10.6%) occurred in maintained patients, 2.0–3.7 months after the last dose and mostly without seroconversion, and none among the older patients without maintenance. Censoring these deaths brought the PFS benefit back within the range of randomised trials (weighted HR 0.41, 0.17–0.96). Conclusions: In this small real-world cohort, COVID-19 mortality appears to have offset much of the expected gain from maintenance during the pandemic.

AntibodiesVol. 15(6)
University of Udine (IT), University of Trieste (IT), Ospedale Santa Maria della Misericordia di Udine (IT), Azienda Sanitaria Universitaria Integrata di Trieste (IT)
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon